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Carcinogenesis is a multistage process involving the inappropriate activation of normal cellular
genes to become oncogenes, e.g., ras, and the inactivation of other cellular genes called tumor
suppressor genes. p53 is the prototypic tumor suppressor gene that is well suited as a molecular
link between the causes of cancer, i.e., carcinogenic chemical and physical agents and certain
viruses, and the development of clinical cancer. The p53 tumor suppressor gene is mutated in the
majority of human cancers. Genetic analysis of human cancer is providing clues to the etiology of
these diverse tumors and to the functions of the p53 gene. Some of the mutations in the p53
gene reflect endogenous causes of cancer, whereas others are characteristic of carcinogens
found in our environment. In geographic areas where hepatitis B virus and a dietary chemical
carcinogen, aflatoxin B1, are risk factors of liver cancer, a molecular signature of the chemical
carcinogen is found in the mutated p53 gene. A different molecular signature in the p53 gene is
found in skin cancer caused by sunlight. Because mutations in the p53 gene can occur in
precancerous lesions in the lung, breast, esophagus, and colon, molecular analysis of the p53
gene in exfoliated cells found in either body fluids or tissue biopsies may identify individuals at
increased cancer risk. p53 mutations in tumors generally indicate a poorer prognosis. In
summary, the recent history of p53 investigations is a paradigm in cancer research, illustrating
both the convergence of previously parallel lines of basic, clinical, and epidemiologic investigation
and the rapid translation of research findings from the laboratory to the clinic. - Environ Health
Perspect 104(Suppl 31:435-439 (1996)
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The crucial differences between normal
and cancer cells stem from discrete changes
in specific genes controlling proliferation
and tissue homeostasis. Over 100 such can-
cer-related genes have been discovered, sev-
eral ofwhich are implicated in the natural
history ofhuman cancer because they are
consistently found mutated in tumors. The
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p53 tumor suppressor gene is the most
striking example because it is mutated in
about halfofalmost all cancer types arising
from a wide spectrum of tissues. Other
tumor suppressor genes important in
human oncology such as APC, WT1,
p16INK4, or NFl may have a more limited
distribution (Table 1); given the variety of
hereditary cancers and allelic deletions
found in human cancers, additional tumor
suppressor genes should be identified in
the future, some ofwhich may also have a
conspicuous role in carcinogenesis.
Tumor suppressor genes are vulnerable
sites for critical DNA damage because
normally they function as physiological
barriers against clonal expansion or geno-
mic mutability and are able to hinder
growth and metastasis of cells driven to
uncontrolled proliferation by oncogenes.
Loss of tumor suppressor function can
occur by damage to the genome through
mutation, chromosomal rearrangement
and nondisjunction, gene conversion,
imprinting, or mitotic recombination.
Tumor suppressor activity can also be
neutralized by interaction with other cellu-
lar proteins or with viral oncoproteins.
Comprehensive reviews of this rapidly
advancing field ofmolecular carcinogenesis
are available (4-6).
The p53 suppressor gene is the most
prominent tumor suppressor gene because
it is mutated in about halfofhuman cancer
cases (7,8). Although the retinoblastoma
and APC tumor suppressor genes are most
commonly inactivated by nonsense muta-
tions that cause the protein to be truncated
or unstable, about 80% ofp53 mutations
are missense mutations that change the
identity ofan amino acid. Changing amino
acids in this way can alter the protein con-
formation and increase the stability ofp53;
it can also alter sequence-specific DNA
binding and transcription factor activity of
p53 (9). One explanation for the high fre-
quency of p53 mutation is that the mis-
sense class of mutations can cause both a
loss of tumor suppressor function and a
gain of oncogenic function by changing
the repertoire of genes whose expressions
are controlled by this transcription factor
(10,11). The central role ofp53 in multi-
stage carcinogenesis places it at the intellec-
tual crossroads ofmolecular carcinogenesis,
molecular epidemiology ofhuman cancer,
and cancer risk assessment.
p53 participates in many cellular
functions: cell cycle control, DNA repair,
differentiation, genomic plasticity, and
programmed cell death (8,10,12). p53 is
one component of the DNA damage
response pathway in mammalian cells
(Figure 1). Some of these normal cellular
functions of p53 can be modulated and
sometimes inhibited by interactions with
either cellular proteins (e.g., mdm2) or
oncoviral proteins (e.g., hepatitis B virus X
protein) of certain DNA viruses. p53 is
clearly a component in a biochemical path-
way or pathways central to human carcino-
genesis, and p53 mutations provide a
selective advantage for clonal expansion of
preneoplastic and neoplastic cells.
The mutation spectrum of p53 in
human cancer can help identify particular
carcinogens and define the biochemical
mechanisms responsible for the genetic
lesions in DNA that cause human cancer.
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Table 1. Examples oftumor suppressorgenes involved in human cancers.a
Tumor Somatic mutations Inherited mutations
suppressor Heterozygote
gene Locus Location/functionb Majortypes Neoplasms Syndrome carrier ratec Typical neoplasms
p53 17pl3.1 Nuclear/transcription Missense Most human cancertypes Li-Fraumeni - 2 Carcinomas of breast
factor examined to date and adrenal cortex;
sarcomas; leukemia;
brain tumors
RB1 13q14 Nuclear/transcription Deletion and Retinoblastoma; Retinoblastoma - 2 Retinoblastoma;
modifier nonsense osteosarcoma; carcinomas osteosarcoma
ofthe breast, prostate,
bladder, and lung
APC 5q21 Cytoplasmic/unknown Deletion and Carcinoma ofthe colon, Familial adenomatous - 10 Carcinomas ofcolon,
nonsense stomach, and pancreas polyposis thyroid and stomach
ATM 11q22 Unknown/kinase Deletion Unknown Ataxia telangiectasia -2 Leukemia; lymphoma
WT1 11p13 Nuclear/transcription Missense Wilms'tumor Wilms tumor 0.5-1 Wilms'tumor
factor
NF1 17ql 1 Cytoplasmic/GTPase Deletion Schwannomas Neurofibromatosis - 30 Neural tumors
activating protein type 1
NF2 22q Cytoplasmic/ Deletion and Schwannomas and Neurofibromatosis - 3 Central schwannomas
cytoskeletal- nonsense meningiomas type 2 and meningiomas
membrane linkage
pl6INK4 9p21 Nuclear/cyclin Deletion and Mesothelioma; pancreas; Familial melanoma ? Melanoma
dependent kinase nonsense melanoma; glioblastoma
inhibitor
VHL 3p25 Nuclear/adaptor Deletiond Unknown von Hippel-Lindau -3 Hemangioblastoma and
renal cell carcinoma
'Data from Savitsky etal.(1); reviewed in Harris etal.(2).hProposed function.cPer 1 births. dDecreased expression controlled byepigenetic mechanism(DNAmethylation)(3).
DNA
damage
+
p53 Mutation
Figure 1. DNA damage leads to p53 accumulation and subsequent changes in gene expression and protein-
protein interactions.
The frequency and type ofp53 mutations
can also act as a molecular dosimeter ofcar-
cinogen exposure and thereby provide infor-
mation about the molecular epidemiology
ofhuman cancer risk. The p53 gene is well-
suited for this form ofmolecular archaeol-
ogy. The majority ofmutations in p53 are
in the hydrophobic midregion ofthe pro-
tein (Figure 2) (8). The function ofthe p53
protein as a transcription factor is exquis-
itely sensitive to conformational changes in
this region that result from amino acid
substitutions (13); p53 binding to other
cellular and oncoviral proteins can easily be
disrupted by mutations in these regions.
How can p53 mutation spectra lead
to identification of the carcinogens that
caused a particular tumor? Different
carcinogens seem to cause different charac-
teristic mutations. Exposure to one com-
mon carcinogen, ultraviolet light, is
correlated with transition mutations at
dipyrimidine sites (14); dietary aflatoxin
B1 exposure is correlated with G:C to T:A
transversions that lead to a serine substitu-
tion at residue 249 ofp53 in hepatocellular
carcinoma (15,16); and exposure to ciga-
rette smoke is correlated with G:C to T:A
transversions in lung carcinomas (17).
How these mutations arise can be fur-
ther tested in the laboratory. For example,
the predominant base changes in p53
found in lung cancers (G:C to T:A trans-
versions) and skin carcinomas (C:G to T:A
transitions) suggest that the causal lesion
likely occurred on the nontranscribed
strand, a finding that is consistent with the
preferential repair after damage ofthe tran-
scribed strand of active genes (18).
Benzo[a]pyrene, a carcinogen in tobacco
smoke, forms DNA adducts that are more
slowly repaired when present on the non-
transcribed strand than on the transcribed
strand of the hypoxanthine (guanine)
phosphoribosyltransferase gene (19), and
ultraviolet light-induced cross-links of
dipyrimidines in the nontranscribed DNA
strand ofthe p53 gene also are more slowly
repaired than in the transcribed strand
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Figure 2. Schematic representation of p53 molecule. Functional domains include the transactivation region (amino
acids 20-42, _), sequence-specific DNA binding region (amino acids 100-293), nuclear localization sequence
(amino acids 316-325, (), and oligomerization region (amino acids 319-360, _). Cellular or oncoviral proteins
bind to specific areas of the p53 protein. Evolutionarily conserved domains (amino acids 17-29, 97-292, and
324-352; _) were determined using the MACAW program. Seven mutational hotspot regions within the large
conserved domain are identified (amino acids 130-142, 151-164, 171-181, 193-200, 213-223, 234-258, and
270-286, _). Vertical lines above the schematic are missense mutations; lines below schematic are nonmis-
sense mutations. The majority of missense mutations are in the conserved hydrophobic midregion, while nonmis-
sense (nonsense, frameshift, splicing, and silent mutations) are distributed throughout the protein, determined
primarily by sequence context.
(20). Because DNA repair rates can be
sequence dependent (21), the p53 muta-
tion spectrum could be influenced by both
the type and location of the promutagenic
lesion. Transcription-repair coupling fac-
tors, the products of the mfd and XPD
gene, have been recently identified and
provide a mechanistic underpinning for
strand-specific repair (22-24). The p53
protein binds to XPB and XPD DNA heli-
cases in the TFIIH complex and modulates
their function in nucleotide excision repair
(25). Another example comes from areas of
China and Mozambique where there is a
high incidence of liver cancer. The high
frequency of G:C to T:A transversions in
human hepatocellular carcinomas in this
region could be due to the high mutability
ofthe third base ofcodon 249 by aflatoxin
B1 or a selective growth advantage ofhepa-
tocyte clones carrying this specific p53
mutant in liver chronically infected with
hepatitis B virus. Indeed, the third base of
codon 249 in a human liver cell line
exposed to aflatoxin B1 is preferentially
mutated (26), and transfected 249se, p53
mutant enhances the growth rate of the
p53 null hepatocellular carcinoma cell
line, Hep3B (27). Other p53 codons show
lower frequencies of G:C to T:A, G:C to
A:T, and G:C to C:G mutations, which
suggests that both preferential mutability
and clonal selection are involved in human
hepatocellular carcinogenesis.
The p53 mutational spectra also can
indicate that a particular cancer did not
result from an environmental carcinogen
but instead was caused by endogenous
mutagenesis. The high frequency ofC to T
transitions at CpG dinucleotides in colon
carcinomas (7) is consistent with mutagen-
esis by endogenous deamination mecha-
nisms. A C to T transition would be
generated by spontaneous deamination of
5-methylcytosine (28) or by enzymatic
deamination of cytosine by DNA (cyto-
sine-5)-methyl transferase when S-adeno-
sylmethionine is in limiting concentration
(or by both mechanisms) (29). Because
oxygen radicals enhance the rate ofdeami-
nation of deoxynucleotides (30,31),
chronic inflammation and nitric oxide gen-
erated by nitric oxide synthases may
explain why rats that inhale particulate
materials, which cause inflammation but
do not act directly on DNA, have a high
incidence oflung cancer.
Mutations in p53 can also reveal that an
individual has an increased susceptibility to
cancer owing to inheritance ofa germ-line
mutation, a concept first proposed for the
retinoblastoma (Rb) tumor suppressor gene
(32). Germline p53 mutations are missense
and occur frequently in the cancer-prone
individuals with Li-Fraumeni syndrome
(33). Laboratory animals with either a
mutant p53 transgene or a deleted p53
gene, i.e., homozygous or heterozygous
gene knockouts, also are particularly sus-
ceptible to cancer (34,35). These mutations
in p53 are associated with instability in the
rest ofthe genome (36). Such instability
could generate multiple genetic alterations
leading to cancer. Indeed, genomic instabil-
ity (including gene amplification) increases
in frequency in cells that lack a normal p53
gene (37,38). Furthermore, loss of the
wild-type alleles ofthe p53 gene abrogates
DNA damage-induced delay of the cell
cycle in G1 (39). DNA repair of certain
promutagenic lesions can proceed prior to
DNA synthesis in S phase. Less time for
repair would increase the frequency of
mutations. Since p53 is an integral compo-
nent in one pathway of programmed
cell death (apoptosis) induced by DNA-
damaging chemotherapeutic drugs or ion-
izing radiation (40,41), inactivation ofp53
could increase both the pool ofprolifer-
ating cells and the probability of their
neoplastic transformation by inhibition of
programmed cell death.
Such progress in the fields ofmolecular
carcinogenesis and molecular epidemiology
increases our ability to accurately assess
cancer risk (Figure 3). Cancer risk assess-
ment, a highly visible discipline in public
health, has historically relied on classical
epidemiology, from chronic exposure of
rodents to potential carcinogens, and the
mathematical modeling ofthese findings.
The field has been forced to steer aprudent
course of conservative risk assessment
because oflimited knowledge ofthe com-
plex pathobiological processes during car-
cinogenesis; differences in the metabolism
of carcinogens, different DNA repair
capacities, variable genomic stability
among animal species, and variation
among individuals with inherited cancer
predisposition have made definitive analy-
sis ofcancer risk almost impossible (5,42).
Because regulatory decisions based on
cancer risk assessments have significant
public health and economic consequences,
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the scientific basis of risk assessment
continues to be, and should continue to
be, actively investigated (43).
Many questions remain. Are the path-
ways ofmolecular carcinogenesis similar in
rodents and humans? Because the time to
develop cancer is generally shorter in
rodents than in humans, could the apparent
interspecies differences be due to the num-
ber of genetic and epigenetic events
required for malignant progression or to the
rate of transit between the events? Is the
more frequent mutation of the ras proto-
oncogenes in rodent cancer a reflection ofa
pathway that is parallel and equivalent to
the p53 pathway in human carcinogenesis?
Are the selective pressures for clonal expan-
sion ofpreneoplastic and neoplastic cells in
human carcinogenesis similar to those in
animal models?
Investigations of the p53 tumor
suppressor gene are an example of the
recent progress in molecular aspects ofcan-
cer research. A better understanding of
molecular carcinogenesis and molecular
epidemiology will eventually decrease the
qualitative and quantitative uncertainties
associated with the current state ofcancer
risk assessment and improve public health
decisions concerning cancer hazards.
Indeed, determination ofthe type and num-
ber ofmutations in p53 and other cancer-
related genes in tissues from healthy people
may allow the identification of those at
increased cancer risk and their consequent
protection by preventive measures.
Laboratory animal studies Cancer epidemiology
Molecular epidemiology
Molecular dosimetry of carcinogen exposure Inherited cancer predisposition
Carcinogen-macromolecular adducts -Genetic polymorphism of enzymes involved
in activation and detoxification ofcarcinogens
Cytogenetic end points - Genomic instability and DNA repair-deficient
Internal exposure assessment Hostsusceptibility assessment
Human cancer risk assessment Bioethical issues
* Hazard identification * Autonomy * Quality
* Dose-response assessment * Privacy * Sensitivity
Justice * Specificity
* Exposure assessment * Equity * Effectiveness
. Risk characterization * Limit genetic testing to conditions
that are correctable by
successful intervention
Intervention and risk management
* Reduce carcinogen exposure
* Increase medical surveillance
* Therapeutic strategies including chemoprevention
* Formulation of health policy
Figure 3. Human cancer risk assessment and bioethical issues associated with molecular epidemiology and
human cancer.
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